|
|
| | VU0155041 Basic information |
| Product Name: | VU0155041 | | Synonyms: | VU0155041;cis-2-[[(3,5-Dichlorophenyl)amino]carbonyl]cyclohexanecarboxylicacid;UV0155041;(1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid;(±)-cis-2-(3,5-DichlorophenylcarbaMoy)cyclohexanecarboxylic Acid;(±)-cis-2-(3,5-Dicholorphenylcarbamoyl)cyclohexanecarboxylic acid;rel-(1R,2S)-2-[[(3,5-Dichlorophenyl)amino]carbonyl]cyclohexanecarboxylic acid;VU0155041;VU-0155041 | | CAS: | 1093757-42-6 | | MF: | C14H15Cl2NO3 | | MW: | 316.18 | | EINECS: | | | Product Categories: | Glutamate | | Mol File: | 1093757-42-6.mol |  |
| | VU0155041 Chemical Properties |
| Boiling point | 540.2±50.0 °C(Predicted) | | density | 1.429±0.06 g/cm3(Predicted) | | storage temp. | Store at RT | | solubility | Soluble to 100 mM in 1eq. NaOH and to 100 mM in DMSO | | form | white powder | | pka | 4.48±0.44(Predicted) |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 |
| | VU0155041 Usage And Synthesis |
| Uses | Acts as an allosteric modulator (PAM) of mGluR4, part of the class of receptors influencing Parkinson’s disease and it’s expression. |
| | VU0155041 Preparation Products And Raw materials |
|